Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Olalekan O Oluwole,Jay Y Spiegel,Brian T Hill,Armin Ghobadi,Joseph P Mcguirk,Saurabh Dahiya,Loretta J Nastoupil,Michael D Jain,Gao Feng,Frederick L Locke,N Nora Bennani,Charalambos Andreadis,Yi Lin,Matthew A Lunning,Aaron P Rapoport,Alison R Sehgal,Abhinav Deol,Julie M Vose ,Sattva S Neelapu ,Michael Jacobs ,Patrick M Reagan ,André Goy ,Javier Muñoz ,Lazaros J Lekakis ,David B Miklos ,Julio C Chávez

doi:10.1182/blood-2019-129624

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Olalekan O Oluwole, Jay Y Spiegel + Show 24 more

Open Access

https://doi.org/10.1182/blood-2019-129624

Copy DOI

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Full Text